Hématologie Leucémie AML LI-1 A PROGRAMME OF DEVELOPMENT FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME Saint-Cloud JACQUES VARGAFTIG
Appareil pulmonaire LUMINOSITY (M14-239) Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer Paris NICOLAS GIRARD
Pédiatrie Tumeurs solides METRO-PD1-1708 Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma Paris ISABELLE AERTS
Sarcomes SARCOME 13 Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response) Paris SOPHIE PIPERNO-NEUMANN
Pédiatrie Sarcomes SARCOME 13 (Pédiatrie) Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response) Paris HELENE PACQUEMENT
Sarcomes BFR ESS 01 Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS Paris SOPHIE PIPERNO-NEUMANN, SOPHIE PIPERNO-NEUMANN
Pédiatrie Tumeurs cérébrales SIOP EPENDYMOMA II An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma Paris FRANCOIS DOZ
Appareil pulmonaire CA224-104 (RELATIVITY) A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Paris NICOLAS GIRARD